Trial Profile
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Vamorolone (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors ReveraGen BioPharma
- 28 Apr 2021 Results (new clinical data of 2.5-year treatment outcome) presented in a Santhera Pharmaceuticals media release.
- 20 May 2020 Results of exposure-response relationships of vamorolone in three studies (VBP15-001, VBP15-002 & VBP15-003) boys with Duchenne muscular dystrophy, published in the Journal of Clinical Pharmacology.
- 26 Aug 2019 Results assessing dose improvement in Duchenne muscular dystropy patients treated with vamorolone in this and other trial (NCT02760277), published in the Neurology.